Sign up to save your podcasts
Or
Share Fixed-Duration Epcoritamab Combination Therapy for Relapsed or Refractory Follicular Lymphoma and Pre-Transplant Strategies for GVHD post-HSCT
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Fixed-Duration Epcoritamab Combination Therapy for Relapsed or Refractory Follicular Lymphoma and Pre-Transplant Strategies for GVHD post-HSCT
In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.
Featured Articles
- Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma
- Pre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT
View all episodes
By American Society of Hematology
4.1
4949 ratings
In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.
Featured Articles
- Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma
- Pre-transplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT
More shows like Blood Podcast
View all
TED Talks Daily
11,015 Listeners
JAMA Editors' Summary
139 Listeners
NEJM This Week
325 Listeners
JAMA Clinical Reviews
498 Listeners
Hematologic Oncology Update
76 Listeners
The Hematologist
28 Listeners
Core IM | Internal Medicine Podcast
1,143 Listeners
VJHemOnc Podcast
2 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
369 Listeners
The Curious Clinicians
374 Listeners
EHA Unplugged
1 Listeners
Blood Cancer Talks
48 Listeners
Two Onc Docs
193 Listeners
WolverHeme Happy Hour
29 Listeners
HemeTalks: Conversations in Hematology Education
4 Listeners